L. Peng et al.
We further studied the oxidative addition step by adding
5-bromotriazole ribonucleoside (1) into the mixed-ligand
catalyst system (Figure 1B, viii). Interestingly, in the pres-
ence of Xantphos, compound 1 preferentially formed the
adduct (Synphos)Pd(1) (Figure 1B, viii) compared with the
single-ligand system with Synphos (Figure 1B, vi). As a
result, the ligand exchange equilibrium could again be shift-
tremely important compounds in the continued quest for an-
tiviral and anticancer drug candidates.
Acknowledgements
ed towards the formation of the (Synphos)PdACTHNURTGNEU(GN dba) complex
Financial support was from the National Mega Project on Major Drug
Development (2009ZX09301-014), Wuhan University, CNRS and
INSERM. YTF is supported by the China Scholarship Council, and YX
by la Fondation pour la Recherche Mꢀdicale. We thank Drs. Gilles Quꢀl-
ꢀver, Hervꢀ Clavier and Ms. Roseline Rosas for their help in the synthe-
sis and 31P NMR investigation.
(Scheme 1B), thus further promoting the reaction. Based on
these results, we could reasonably conclude that, in the Pd/
Synphos single-ligand system, it is not that the catalytic spe-
cies has lower catalytic activity, but rather that the single-
ligand system with Synphos generates only a limited amount
of active catalytic species. In the mixed-ligand system, Xant-
phos promotes the formation of active catalytic species
formed between Pd and Synphos, thus leading to powerful
catalytic activity (Scheme 1A). In addition, using this mixed-
ligand system, the substrate preferentially formed adduct
Keywords: antitumor agents
·
arylamination
·
cross-
coupling · nucleosides · palladium
with the (Synphos)PdACHTNUGRTENUNG(dba) complex, further favoring the
[1] a) Modified Nucleosides in Biochemistry Biotechnology and Medi-
cine, (Ed.: P. Herdewijn), Wiley-VCH, Weinheim, Germany, 2008;
b) C. M. Galmarini, F. Popowycz, B. Joseph, Curr. Med. Chem. 2008,
15, 1072–1082.
equilibrium shift towards the formation of active catalyst
(Scheme 1B). Altogether, the 31P NMR studies provided
crucial data with which we were able to better understand
the origin of the enhanced catalytic effect displayed by this
[2] a) Y. Xia, F. Qu, L. Peng, Mini-Rev. Med. Chem. 2010, 10, 806–821;
b) J. Wan, Y. Xia, Y. Liu, M. Wang, P. Rocchi, J. Yao, F. Qu, J.
c) Y. Xia, Y. Liu, J. Wan, M. Wang, P. Rocchi, F. Qu, J. L. Iovanna,
Li, M. Cong, A. Maggiani, P. Leyssen, F. Qu, J. Neyts, L. Peng,
Z. Fan, Y. Fu, L. Feng, J. Yao, A. Maggiani, Y. Xia, F. Qu, L. Peng,
J. L. Iovanna, L. Peng, Drug Discov. Today 2011, 17, 35–43.
[3] a) Y. Fan, Y. Xia, J. Tang, P. Rocchi, F. Qu, J. Iovanna, L. Peng, Org.
À
mixed-ligand system to promote C N coupling. Based on all
these results presented above, we hence proposed a general
mechanism of this mixed-ligand system assisted C-N cou-
pling involving two independent catalytic cycles between
which Pd is shuttled (see the Supporting Information,
Scheme S1). This mechanism parallels the one proposed by
Buchwald et al, which was formulated on the basis of prod-
uct analysis by trapping the reactive intermediates.[5]
Finally, we also assessed the newly synthesized N-arylami-
notriazole ribonucleosides for their anticancer activity
against drug-resistant pancreatic cancer MiaPaCa-2 cells.
Compound 1c exhibited particularly interesting anticancer
activity (see the Supporting Information, Figure S1), with
superior potency compared to gemcitabine, the current clini-
cal drug used to treat pancreatic cancer.[15] This finding fur-
ther confirmed and warranted the interest in and impor-
tance of developing efficient catalytic systems for synthesiz-
ing this special family of nucleoside analogues.
[4] W. Li, Y. Fan, Y. Xia, P. Rocchi, R. Zhu, F. Qu, J. Neyts, J. L. Iovan-
4974–4977; c) D. A. Wilson, C. J. Wilson, C. Moldoveanu, A. M. Re-
smerita, P. Corcoran, L. M. Hoang, B. M. Rosen, V. Percec, J. Am.
Zhang, X. Wei, J. Savoie, N. D. Patel, N. K. Yee, C. H. Senanayake,
[7] We first tried the Pd/Ruphos/Brettphos system reported by Buch-
wald (see Ref. [5]). However, no satisfactory results were obtained
for synthesizing N-aryltriazole nucleosides. This might be ascribed
to the particularly reluctant reactivity of the heterocyclic triazole
system.
In conclusion, we have disclosed a highly efficient mixed-
ligand Pd catalytic system for arylamination of triazole nu-
cleoside analogues. It is worth mentioning that the Pd/Syn-
phos/Xantphos catalytic system displayed the unparalleled
À
advantage of catalyzing C N cross-coupling of different tria-
zole nucleosides and arylamines. In addition, this catalytic
À
system was also powerful at effectively promoting C N cou-
[9] P. F. Thomson, P. Lagisetty, J. Balzarini, E. De Clercq, M. K. Laksh-
[11] L. M. Klingensmith, E. R. Strieter, T. E. Barder, S. L. Buchwald, Or-
[12] The total ligand concentration remained the same in the multi-
ligand system as in the single-ligand systems.
pling with other halopurine nucleosides including the notori-
ously less reactive chloropurine ribonucleoside. Further-
more, 31P NMR studies provided us with an insightful under-
standing of the mechanism underlying the catalytic power
displayed by the Pd/Synphos/Xantphos system in promoting
arylamination. We anticipate a fueled interest in the mixed-
ligand approach, which may be applicable to other cross-
coupling reactions for the synthesis of structurally diverse
nucleoside analogues, which are currently a class of ex-
2224
ꢁ 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Chem. Eur. J. 2012, 18, 2221 – 2225